This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Mosca, M Articles by Bombardieri, S Search for Related Content PubMed PubMed Citation Articles by Mosca, M Articles by Bombardieri, S Social Bookmarking                         What's this?

The validity of the ECLAM index for the retrospective evaluation of disease activity in systemic lupus erythematosus

Clinical Immunology Unit, Department of Internal Medicine, University of Pisa, via Roma 67, 56126 Pisa, Italy. Tel: (+39) 050 99 25 19, (+39) 050 40124; Fax: (+39) 050 55.86.31; martasssup.it

W Bencivelli

C Vitali

P Carrai

R Neri

S Bombardieri

Clinical Immunology and Rheumatology Unit, Department of Internal Medicine, University of Pisa, Italy

Aim: To determine whether the European Consensus Lupus Activity Measurement Index (ECLAM) can be used to evaluate disease activity in patients retrospectively from the data provided in their clinical charts.

Methods: The ECLAM score was calculated twice in a series of 64 consecutive SLE patients: first for each patient during the course of a standard clinical evaluation (direct-ECLAM), and then one to two weeks later solely on the basis of the data provided in the patient's clinical chart (chart-ECLAM). The scorings for each patient were performed by two different assessors.

Results: The direct-ECLAM and chart-ECLAM scores were highly correlated (Spearman's rank correlation coefficient = 0.86). The regression line was not significantly different from the identity line (t-test). The Pearson's coefficient was 0.88. The interobserver variability of the chart-ECLAM showed a low inter-rater variability.

Conclusion: ECLAM could represent a valid and reliable instrument for the retrospective analysis of disease activity in SLE patients.

Key Words: ECLAM • retrospective calculation • disease activity

Lupus, Vol. 9, No. 6, 445-450 (2000)
DOI: 10.1191/096120300678828640


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				C Gordon, G Bertsias, J P A Ioannidis, J Boletis, S Bombardieri, R Cervera, C Dostal, J Font, I-M Gilboe, F Houssiau, et al. EULAR points to consider for conducting clinical trials in systemic lupus erythematosus Ann Rheum Dis, April 1, 2009; 68(4): 470 - 476. [Abstract] [Full Text] [PDF]

				G K Bertsias, J P A Ioannidis, J Boletis, S Bombardieri, R Cervera, C Dostal, J Font, I M Gilboe, F Houssiau, T Huizinga, et al. EULAR points to consider for conducting clinical trials in systemic lupus erythematosus: literature based evidence for the selection of endpoints Ann Rheum Dis, April 1, 2009; 68(4): 477 - 483. [Abstract] [Full Text] [PDF]

				N. Mozaffarian, A. E. Wiedeman, and A. M. Stevens Active systemic lupus erythematosus is associated with failure of antigen-presenting cells to express programmed death ligand-1 Rheumatology, September 1, 2008; 47(9): 1335 - 1341. [Abstract] [Full Text] [PDF]

				H. Tanaka, E. Oki, K. Tsugawa, K. Nonaka, K. Suzuki, and E. Ito Effective treatment of young patients with pediatric-onset, long-standing lupus nephritis with tacrolimus given as a single daily dose: an open-label pilot study Lupus, November 1, 2007; 16(11): 896 - 900. [Abstract] [PDF]

				P. Bartolucci, S. Brechignac, P. Cohen, V. Le Guern, and L. Guillevin Adjunctive plasma exchanges to treat neuropsychiatric lupus: a retrospective study on 10 patients Lupus, October 1, 2007; 16(10): 817 - 822. [Abstract] [PDF]

				P D Ziakas, L S Poulou, S Giannouli, A G Tzioufas, and M Voulgarelis Thrombocytopenia in lupus: baseline C3 as an independent risk factor for relapse Ann Rheum Dis, January 1, 2007; 66(1): 130 - 131. [Full Text] [PDF]

				P. D. Ziakas, U. G. Dafni, S. Giannouli, A. G. Tzioufas, and M. Voulgarelis Thrombocytopaenia in lupus as a marker of adverse outcome--seeking Ariadne's thread Rheumatology, October 1, 2006; 45(10): 1261 - 1265. [Abstract] [Full Text] [PDF]

				M. Y. Karim, C. N. Pisoni, L. Ferro, M. F. Tungekar, I. C. Abbs, D. P. D'Cruz, M. A. Khamashta, and G. R. V. Hughes Reduction of proteinuria with mycophenolate mofetil in predominantly membranous lupus nephropathy Rheumatology, October 1, 2005; 44(10): 1317 - 1321. [Abstract] [Full Text] [PDF]

				P D Ziakas, S Giannouli, E Zintzaras, A G Tzioufas, and M Voulgarelis Lupus thrombocytopenia: clinical implications and prognostic significance Ann Rheum Dis, September 1, 2005; 64(9): 1366 - 1369. [Abstract] [Full Text] [PDF]

				S Fineschi, M O Borghi, P Riboldi, M Gariglio, C Buzio, S Landolfo, L Cebecauer, A Tuchynova, J Rovensky, and P L Meroni Prevalence of autoantibodies against structure specific recognition protein 1 in systemic lupus erythematosus Lupus, June 1, 2004; 13(6): 463 - 468. [Abstract] [PDF]

				F Forger, T Matthias, M Oppermann, H Becker, and K Helmke Clinical significance of anti-dsDNA antibody isotypes: IgG/IgM ratio of anti-dsDNA antibodies as a prognostic marker for lupus nephritis Lupus, January 1, 2004; 13(1): 36 - 44. [Abstract] [PDF]